Brokerages Set Smith & Nephew plc (NYSE:SNN) Target Price at $28.00

Shares of Smith & Nephew plc (NYSE:SNN - Get Free Report) have been given a consensus recommendation of "Hold" by the six brokerages that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold rating. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $28.00.

SNN has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a report on Wednesday, February 26th. HSBC lowered shares of Smith & Nephew from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. UBS Group lowered shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. Hsbc Global Res lowered shares of Smith & Nephew from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Canaccord Genuity Group boosted their price target on shares of Smith & Nephew from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st.

Institutional Trading of Smith & Nephew

Large investors have recently made changes to their positions in the company. Hexagon Capital Partners LLC increased its stake in shares of Smith & Nephew by 63.3% during the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock worth $30,000 after buying an additional 406 shares during the period. Richards Merrill & Peterson Inc. increased its stake in shares of Smith & Nephew by 500.0% during the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock worth $34,000 after buying an additional 1,000 shares during the period. Principal Securities Inc. increased its stake in shares of Smith & Nephew by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock worth $36,000 after buying an additional 691 shares during the period. National Bank of Canada FI increased its stake in shares of Smith & Nephew by 36.5% during the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after buying an additional 446 shares during the period. Finally, Bessemer Group Inc. increased its stake in shares of Smith & Nephew by 3,471.4% during the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after buying an additional 1,701 shares during the period. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew Trading Down 2.6%

SNN traded down $0.79 on Friday, hitting $29.33. The company had a trading volume of 838,174 shares, compared to its average volume of 800,171. The firm has a market cap of $12.84 billion, a P/E ratio of 13.58, a PEG ratio of 1.26 and a beta of 0.68. Smith & Nephew has a 1 year low of $23.69 and a 1 year high of $31.72. The company's fifty day moving average price is $27.95 and its 200 day moving average price is $26.85. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.